中國太平(00966.HK):太平人壽無固定期限資本債券發行完畢
格隆匯3月21日丨中國太平(00966.HK)發佈公吿,有關公司的附屬公司太平人壽保險有限公司(“太平人壽”)擬發行無固定期限資本債券,太平人壽已於2023年12月21日及2025年3月21日在全國銀行間債券市場發行完畢2期總額合共為人民幣200億元的無固定期限資本債券(“該債券”)。該債券票面利率分別為每年3.30%及2.40%,自發行繳款截止日起每5年調整一次,在第5年及的後的每個付息日附太平人壽有條件贖回權。
發行該債券所募集的資金將依據適用法律和監管部門的批准用於補充太平人壽核心二級資本,提高太平人壽償付能力,為太平人壽業務的良性發展創造條件,支持業務持續穩健發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.